|
Transcept Pharmaceuticals may not make a bitter pill easier to swallow, but it'll make the pill more effective once it's inside. The company's drug delivery technology enhances absorption rates of active drug agents, reducing absorption times, as well as the time it takes for the drug to take effect. The company targets medications where rapid absorption would significantly benefit treatment, including central nervous system and psychiatric disorders. Lead product candidate Intermezzo offers a quick-acting, low-dosage medication for treating insomnia that occurs in the middle of the night. Transcept contracts with third parties for manufacturing and packaging. The company merged with publicly held Novacea in 2009.
|
| | | Contact Information | |
Address: |
1003 W. Cutting Blvd., Ste. 110
Port Richmond, CA 94804
| | Phone: | 510-215-3500 | | Fax: | 510-215-3535 |
|
| Financial
Highlights | | Revenue (2008): | 60.60 M | | Revenue Growth (1 yr): | 263.40% | | Employees (2008): | 33 | | Employee Growth (1 yr): | (-48.40%) |
|
|
Key People
| | • |
Chairman:
G. Kirk Raab
| | • |
President, CEO, and Director:
Glenn A. Oclassen
| | • |
SVP Operations and CFO:
Thomas P. Soloway
|
|
|
